Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T, Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: ak n. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083. Epub 2022 Jun 23. Future Oncol. 2022. PMID: 35734870
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö, Mustafayev FNA, Yaman Ş, Bayram E, Ertürk İ, Özcan E, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, Baytemür NK, Gülmez A, Aydın D, Şakalar T, Arak H, Tatlı AM, Ergün Y, Ak N, Ünal Ç, Özgün MA, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: ak n. J Cancer Res Clin Oncol. 2023 Jul;149(8):4141-4148. doi: 10.1007/s00432-022-04252-2. Epub 2022 Sep 1. J Cancer Res Clin Oncol. 2023. PMID: 36048274
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy.
Oner G, Önder S, Karatay H, Ak N, Tükenmez M, Müslümanoğlu M, İğci A, Dincçağ A, Özmen V, Aydiner A, Yavuz E, Cabioğlu N. Oner G, et al. Among authors: ak n. World J Surg Oncol. 2023 Feb 21;21(1):54. doi: 10.1186/s12957-023-02931-z. World J Surg Oncol. 2023. PMID: 36810121 Free PMC article. No abstract available.
Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients.
Dogan I, Aydin E, Khanmammadov N, Paksoy N, Ferhatoğlu F, Ak N, Emiroglu S, Ibis K, Onder S, Tukenmez M, Cabioglu N, Kucucuk S, Muslumanoğlu M, Ozmen V, Saip P, Igci A, Aydiner A. Dogan I, et al. Among authors: ak n. J Cancer Res Clin Oncol. 2023 Nov;149(16):14833-14841. doi: 10.1007/s00432-023-05276-y. Epub 2023 Aug 18. J Cancer Res Clin Oncol. 2023. PMID: 37594533
MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.
Ünal Ç, Özmen T, İlgün AS, Ordu Ç, Özkurt E, Ak N, Alço G, Erdoğan İyigün Z, Kurt S, Duymaz T, Öztürk MA, Elbüken Çelebi F, Yararbaş K, Soybir G, Aktepe F, Özmen V. Ünal Ç, et al. Among authors: ak n. Breast Cancer (Dove Med Press). 2023 Sep 1;15:659-669. doi: 10.2147/BCTT.S421535. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 37674872 Free PMC article.
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Ünal Ç, Azizy A, Karabulut S, Taştekin D, Akyıldız A, Yaşar S, Yalçın Ş, Çoban E, Evrensel T, Kalkan Z, Oruç Z, Derin S, Turna ZH, Bayram D, Köş FT, Şendur MAN, Sever N, Ercelep Ö, Seyyar M, Kefeli U, Uygun K, Özçelik M, Ön S, Şanlı UA, Canaslan K, Ünek İT, Yücel KB, Özdemir N, Yazıcı O, Güzel HG, Salim DK, Göksu SS, Tatlı AM, Ordu Ç, Selvi O, Sakin A, Büyükbayram ME, Dursun B, Ürün Y, Arak H, Ağdaş G, Uğraklı M, Hendem E, Eryılmaz MK, Bilgin B, Topçu A, Şimşek M, Büyükşimşek M, Akay B, Erdal GŞ, Karataş F, Alan Ö, Çağlayan M, Kahvecioğlu FA, Demirci A, Paksoy N, Çetin B, Gümüş M, Ak N, Aydınalp Y, Paydaş S, Güven DC, Kılıçkap S, Sağlam S. Ünal Ç, et al. Among authors: ak n. Oncologist. 2023 Oct 3;28(10):875-884. doi: 10.1093/oncolo/oyad257. Oncologist. 2023. PMID: 37676712 Free PMC article.
The Relationship of Pathological Response and Visceral Muscle and Fat Volume in Women With Breast Cancer Who Received Neoadjuvant Chemotherapy.
Kayan Tapan T, Çelebi F, Yaghouti K, Ağaçayak F, İlgün S, Soybir G, Alço G, Ak N, Ordu Ç, Özkurt E, Ünal Ç, Kurt S, Öztürk A, İyigün Z, Duymaz T, Özmen V. Kayan Tapan T, et al. Among authors: ak n. Eur J Breast Health. 2024 Apr 1;20(2):117-121. doi: 10.4274/ejbh.galenos.2024.2023-12-5. eCollection 2024 Apr. Eur J Breast Health. 2024. PMID: 38571683 Free PMC article.
51 results